Drug Trial Radar · NCT03293069
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
372
Actual
Start
Jan 30, 2019
Primary completion
Nov 11, 2023
Study completion May 6, 2024
Sponsor
- Lead sponsor
- University Hospital, LilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Sep 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The alteration of iron metabolism is reported in animal models of amyotrophic lateral sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS. The high iron concentration of the brain, due to its high energy demand (high oxygen consumption), makes motor neurons particularly vulnerable to energy deficit and oxidative stress. Post-mortem examinations and MRI scans in patients with ALS have found signs of iron accumulation in the central motor tract; and a high level of serum ferritin, which is a marker of iron levels, is associated with a lower prognosis. In ALS mouse models, the use of iron chelators has demonstrated neuroprotection and increased life expectancy, suggesting that elimination of excess iron from the brain can prevent neuronal loss and, consequently, a slow progression of the disease. Conservative chelation of iron refers to a modality whereby much of the iron that binds to the chelator is redistributed in the body rather than exhausted. Using a chelator, deferiprone, with this feature, in a safety pilot study, a very good safety profile was observed. Deferiprone eliminated excess iron from brain regions, reduced oxidative damage and cell death associated with regional iron deposits with no apparent negative impact on the iron levels needed. Now, the efficacy of this new therapeutic modality of neuroprotection is being evaluated in a randomized, double-blind, placebo-controlled, multicenter study.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
DeferiproneDrug
One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
Placebo Oral TabletDrug
the placebo twice daily morning and evening.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CAFS score (Combined Assessment of Function and Survival)Time frame: at 12 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Chr Angers
Angers, France
Chru Brest
Brest, France
Hopital Pierre Wertheimer - Hcl - Bron
Bron, France
Chu Cote de Nacre - Caen
Caen, France
Chu de Clermont-Ferrand
Clermont-Ferrand, France
Hôpital Roger Salengro, CHU
Lille, France
C H U Dupuytren Limoges
Limoges, France
Aphm Hopital La Timone
Marseille, France
Chu de Nancy
Nancy, France
Chu de Nice Hopital Pasteur
Nice, France
Hu Pitie Salpetriere Aphp
Paris, France
Hopital de Hautepierre
Strasbourg, France
Chu de Bordeaux - Talence
Talence, France
Chu Toulouse
Toulouse, France
Chu de Tours
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.